United States Eosinophilic Esophagitis (Eoe) Market Opportunity Assessment And Forecast Report 2025: Novel Biologics, Advanced Corticosteroids And Pediatric Adoption Drive Growth

2025-09-30 11:31:50

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in the US EoE market include the expansion and adoption of biologics and novel corticosteroid formulations, serving pediatric and mild-to-moderate cases. Companies focusing on durable efficacy and patient-friendly regimens can gain a competitive edge in this growing, underexplored sector.

Dublin, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The "Eosinophilic Esophagitis (EoE): Opportunity Assessment and Forecast - Update" report has been added to ResearchAndMarkets's offering.
The US EoE market is expected to grow to driven by the introduction of biologics and the late-stage pipeline.

The current standard of care for EoE includes proton pump inhibitors, swallowed topical corticosteroids, and dietary elimination approaches. While biologics such as dupilumab have introduced new options, many patients experience partial response, relapse upon treatment discontinuation, or challenges with long-term adherence to dietary regimens.

Market growth will be underpinned by novel biologics and advanced topical corticosteroid formulations, alongside broader adoption of pediatric and mild-to-moderate patient treatment. Companies demonstrating durable efficacy and patient-centric outcomes are expected to capture share in this evolving, underpenetrated market.
Scope

Overview of EoE, including epidemiology, symptoms, diagnosis, and disease management.
Annualized EoE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the EoE market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for EoE. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the US EoE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the US EoE therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EoE therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Key Topics Covered:

Abbreviations
Related Reports
Summary of Updates
Executive Summary
Disease Overview
Overview of Eosinophilic Esophagitis
Etiology of EoE
Pathophysiology of EoE
Classification of EoE
Diagnostic Paradigm
Diagnosis: KOL Insights
EoE SWOT Analysis
Epidemiology
Lifetime Diagnosed Prevalent Cases of EoE, All Ages, Both Sexes, 2020-30
Sources and Methodology for Lifetime Diagnosed Prevalent Cases of EoE
Sources and Methodology - Lifetime Diagnosed Prevalent Cases of EoE
Current Treatment Options
Treatment Paradigm
Current Treatments for EoE
Product Profile: Proton Pump Inhibitors (PPI)
Product Profile: Glucocorticoid Receptor Agonist (GRA)
Product Profile: Dupixent (dupilumab)
Product Profile: Eohilia (budesonide)
Unmet Needs and Opportunities
Unmet Needs in EoE
Non-invasive Monitoring Tools
Durable Disease Control and Efficacy
Access and Affordability
R&D Strategies
Trends in Clinical Trial Design in EoE
Trends in Deal-Making in EoE
Top 10 Deals for EoE
Pipeline Assessment
EoE Pipeline Overview
Late-Stage Pipeline Agents for EoE
Product Profile: Ellodi's APT-1011 (fluticasone)
Product Profile: Amgen's Tezspire (tezepelumab)
Clinical Trials in the EoE Space
Market Outlook
EoE Market Forecast (1/2)
EoE Market Forecast (2/2)
US Market Drivers and Barriers
Appendix

Companies Featured

Amgen GmbH
Sanofi
Takeda GmbH
Ellodi Pharmaceuticals

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN30092025004107003653ID1110131425

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.